-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tivozanib in Diabetic Macular Edema
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tivozanib in Diabetic Macular Edema report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tivozanib in Diabetic Macular Edema Drug Details: Tivozanib is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tivozanib in Wet (Neovascular / Exudative) Macular Degeneration
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tivozanib in Wet (Neovascular / Exudative) Macular Degeneration report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tivozanib in Wet (Neovascular / Exudative) Macular...
-
Product Insights
NewNet Present Value Model: Ionis Pharmaceuticals Inc’s Evazarsen Sodium
Empower your strategies with our Net Present Value Model: Ionis Pharmaceuticals Inc's Evazarsen Sodium report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rocatinlimab in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rocatinlimab in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rocatinlimab in Atopic Dermatitis (Atopic Eczema) Drug Details: Rocatinlimab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mogamulizumab in Peripheral T-Cell Lymphomas (PTCL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mogamulizumab in Peripheral T-Cell Lymphomas (PTCL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mogamulizumab in Peripheral T-Cell Lymphomas (PTCL) Drug Details: Mogamulizumab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rocatinlimab in Asthma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rocatinlimab in Asthma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rocatinlimab in Asthma Drug Details: Rocatinlimab is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Cedazuridine + Decitabine) in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Cedazuridine + Decitabine) in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Cedazuridine + Decitabine) in Solid Tumor Drug Details: Cedazuridine...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KK-2269 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KK-2269 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KK-2269 in Solid Tumor Drug Details: KK-2269 is under development for...
-
Product Insights
NewNet Present Value Model: Kyowa Kirin Co Ltd’s Rocatinlimab
Empower your strategies with our Net Present Value Model: Kyowa Kirin Co Ltd's Rocatinlimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewQuarterly Carbonates pricing trends in Brazil
Empower your strategies with our Quarterly Carbonates pricing trends in Brazil report and make more profitable business decisions. Consumers’ preferences for stores are most heavily influenced by pricing and promotions, but brands and retailers continue to adjust prices and promotions based on insufficient information from expensive, drawn-out, and incomplete audits of rival techniques. Brands and retailers can benefit from the unique intelligence provided by GlobalData Ecommerce Price Tracker, covering millions of SKUs, to identify, anticipate, and implement important business choices....